Gynecologic Oncology Unit, Department of Oncology, Catholic University, Campobasso, Italy; Gynecologic Oncology Unit, Catholic University, Rome, Italy.
Eur J Surg Oncol. 2012 Mar;38(3):238-44. doi: 10.1016/j.ejso.2011.12.001. Epub 2011 Dec 24.
The study aimed at describing the prevalence, and pattern of comorbidities, as well as their clinical role in a large series of locally advanced cervical cancer (LACC) patients triaged to preoperative chemoradiation.
The Charlson index (CCI), and the ACE27 index were used to retrospectively evaluate comorbidities in 258 LACC patients: life tables were computed by the Kaplan-Meier method; multivariate analysis was performed by Cox's regression model.
A CCI score = 0 was documented in 225 patients (87.2%), while 24 patients (9.3%) had a CCI score = 1, and only 9 patients (3.5%) had a CCI score ≥ 2. An ACE27 score = 0 was documented in 170 patients (65.9%), and was 1 in 59 patients (22.8%), 2 in 24 patients (9.3%) and 3 in 5 patients (2%). There was no association between the presence of comorbidities and clinico-pathological variables with the exception of a direct association with older age. There was no difference in the distribution of comorbid cases according to the extent of hysterectomy and lymphadenectomy. DFS or OS curves did not differ in patients with or without comorbidities according to both indexes. No difference in the distribution of patients with comorbidities according to presence of complications was documented.
The role of comorbidities in the decision-making process relative to the enrollment of LACC patients into this trimodal therapeutic strategy needs to be established in specifically designed prospective trials.
本研究旨在描述大量局部晚期宫颈癌(LACC)患者接受术前放化疗的分类中,合并症的流行情况、模式及其临床作用。
使用 Charlson 指数(CCI)和 ACE27 指数回顾性评估 258 例 LACC 患者的合并症:采用 Kaplan-Meier 法计算生存表;采用 Cox 回归模型进行多变量分析。
225 例患者(87.2%)CCI 评分为 0,24 例患者(9.3%)CCI 评分为 1,仅 9 例患者(3.5%)CCI 评分为≥2。170 例患者(65.9%)ACE27 评分为 0,59 例患者(22.8%)评分为 1,24 例患者(9.3%)评分为 2,5 例患者(2%)评分为 3。除了与年龄较大直接相关外,合并症的存在与临床病理变量之间没有关联。根据子宫切除术和淋巴结切除术的范围,合并症病例的分布没有差异。根据这两个指标,有合并症和无合并症的患者的 DFS 或 OS 曲线没有差异。根据并发症的存在,没有记录到合并症患者的分布有差异。
在专门设计的前瞻性试验中,需要确定合并症在决定局部晚期宫颈癌患者是否纳入这种三模式治疗策略中的作用。